Margaretta Masse, MD
Dermatology · New Hyde Park, NYNPI 1831652528
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,900 of the $5,511 with a category attached, or 70.8%. Boehringer Ingelheim accounts for 92.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $5,050 and has fallen 97.9% since, to $105 in 2025.
Across 22 payments — averaging $250.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- AbbVie$178
- Lilly USA, LLC$106
- Johnson & Johnson$73
- E.r. Squibb & Sons, L.L.C.$31
- Regeneron Healthcare Solutions, Inc.$24
- plus $23 from 1 others
What the payments were for
- Consulting fees$3,90071%
- Travel & lodging$90116%
- Food & beverage$71013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $5,075 |
| AbbVie | 5 | $178 |
| Lilly USA, LLC | 4 | $106 |
| Johnson & Johnson | 2 | $73 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
How this compares
$5,511 in reported general payments places this provider in the 65th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 25 | $87,342 |
| Tacrolimus | 22 | $3,697 |
| Ketoconazole | 174 | $3,567 |
| Clobetasol Propionate | 31 | $1,715 |
| Triamcinolone Acetonide | 82 | $1,181 |
| Clindamycin Phosphate | 30 | $1,003 |
| Fluocinonide | 24 | $904 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 19 | $896 |
| Mometasone Furoate | 45 | $844 |
| Fluorouracil | 13 | $769 |
| Ammonium Lactate | 17 | $429 |
| Hydrocortisone | 70 | $356 |
| Mupirocin | 42 | $352 |
| Finasteride | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Hyde Park
- Amit GargNew Hyde Park$453K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.